Biocytogen Pharmaceuticals Beijing (2315) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
29 Oct, 2026Executive summary
9M revenue RMB1,402.8m, up 49.09% YoY; net profit attributable to shareholders RMB312.45m, up 173.77%, and adjusted net profit RMB235.49m, up 307.62%.
Q3 revenue RMB461.37m, up 44.22% YoY; attributable net profit RMB71.36m, up 7.91%, and adjusted net profit RMB38.04m, up 30.19%.
Financial highlights
9M operating profit RMB325.93m vs RMB129.68m in 2025; total profit RMB325.55m vs RMB129.08m; net profit RMB312.45m vs RMB114.13m.
Non-recurring profit or loss totaled RMB76.96m for 9M and RMB33.32m for Q3, mainly from fair-value changes and disposals of biological assets and structured deposits.
Segment performance
Growth in pharmacology and efficacy services and animal models was cited as the main driver of revenue growth in Q3 and across 9M.
Latest events from Biocytogen Pharmaceuticals Beijing
- Revenue rose 25.6%, net loss narrowed 73.3%, and operating cash flow turned positive.2315
H1 2024 - Revenue growth and cost discipline drove a return to profit and positive operating cash flow.2315H2 2024
- Revenue rose 51.3% as earnings and operating cash flow turned positive.2315H1 2025
- Revenue surged 40.6%, profit more than quintupled, and A-share proceeds expanded capacity.2315H2 2025
- Revenue rose 51.6%, while net profit increased more than fivefold on strong model and antibody growth.2315H1 2026
- Revenue surged 73.68% and net profit attributable to shareholders reached RMB104.0m.2315Q1 2026